|Articles|March 22, 2021
Nephron Pharmaceuticals Integrates STERIS VHP Biodecontamination System
Author(s)STERIS Life Sciences
This case study examines the benefits and challenges Nephron Pharmaceuticals Corporation faced integrating a STERIS VHP® Biodecontamination system into their high-volume compounding facility.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
2
Charles River Incubator Cohort to Accelerate CGT Development
3
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
4
FAQ: Shifts in FDA Regulations and Strategies in 2025
5
